Ontario: simplifying to rely on tumor volume and AFP ˂ 1000 ng/mL, Edmonton: identical criteria with modifications in lowered tumor volume and AFP ≤ 400 ng/mL requirements, Toronto: more serious expansion obliterating Milan size and number tumor restrictions and AFP ≤ 500 ng/mL, and Metroticket 2.0: corresponding the tumors directly to AFP value (Figure 1). This evidence concerns the gene AFP and neoplasm.